指南与共识淋巴瘤MDS 与骨髓增殖性肿瘤

国际循证共识:HHV-8阴性/特发性多中心Castleman病的诊断标准

International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.
指南 / 共识 · Blood · 2017-01-13

一个由8个国家34名儿童及成人病理与临床专家(含2名iMCD患者医生)组成的国际工作组,复习244例病例、经两次会议及15个月(2015年6月至2016年9月)修订,提出HHV-8阴性/特发性多中心Castleman病(iMCD)的共识诊断标准,要求同时满足主要标准、11项次要标准中至少2项(含至少1项实验室异常)并排除 mimic 疾病。

要点

  • iMCD诊断需同时满足主要标准:特征性淋巴结组织病理学及多中心淋巴结肿大。
  • 次要标准共11项,须满足至少2项且至少1项为实验室异常。
  • 须排除可模拟iMCD的感染性、恶性及自身免疫性疾病。

核心结论

  • iMCD共识诊断标准将促进一致的诊断、适当的治疗和协作研究。

研究设计与样本

  • 国际工作组由8个国家34名儿童及成人病理与临床专家组成,其中包括2名同时也是iMCD患者的医生。
  • 工作组复习了244例病例的数据,召开两次会议,并在15个月(2015年6月至2016年9月)内对标准进行修订。

主要发现

  • iMCD占所有MCD病例的三分之一至二分之一,可发生于任何年龄的个体。
  • iMCD是一种罕见且危及生命的疾病,涉及全身炎症症状、多克隆淋巴增殖、血细胞减少和多器官系统功能障碍,由常包括白细胞介素-6的细胞因子风暴引起。
  • 准确诊断具有挑战性,因为目前尚无标准诊断标准或诊断生物标志物,且与恶性、自身免疫和感染性疾病存在显著重叠。

关键数值与推荐

  • 共识标准要求同时满足主要标准:特征性淋巴结组织病理学和多中心淋巴结肿大。
  • 须满足11项次要标准中的至少2项,且至少1项为实验室异常。
  • 须排除可模拟iMCD的感染性、恶性和自身免疫性疾病。
  • 特征性组织病理学特征可包括退化和增生性生发中心、滤泡树突细胞突出、血管增生和多型性浆细胞增多症的复合表现。
  • 实验室和临床次要标准包括:C反应蛋白或红细胞沉降率升高、贫血、血小板减少或血小板增多、低白蛋白血症、肾功能不全或蛋白尿、多克隆性高丙种球蛋白血症、体质性症状、肝脾肿大、积液或水肿、 eruptive cherry hemangiomatosis 或紫罗兰色丘疹、淋巴细胞性间质性肺炎。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Human herpesvirus-8 (HHV-8)-negative, idiopathic multicentric Castleman disease (iMCD) is a rare and life-threatening disorder involving systemic inflammatory symptoms, polyclonal lymphoproliferation, cytopenias, and multiple organ system dysfunction caused by a cytokine storm often including interleukin-6. iMCD accounts for one third to one half of all cases of MCD and can occur in individuals of any age. Accurate diagnosis is challenging, because no standard diagnostic criteria or diagnostic biomarkers currently exist, and there is significant overlap with malignant, autoimmune, and infectious disorders. An international working group comprising 34 pediatric and adult pathology and clinical experts in iMCD and related disorders from 8 countries, including 2 physicians that are also iMCD patients, was convened to establish iMCD diagnostic criteria. The working group reviewed data from 244 cases, met twice, and refined criteria over 15 months (June 2015 to September 2016). The proposed consensus criteria require both Major Criteria (characteristic lymph node histopathology and multicentric lymphadenopathy), at least 2 of 11 Minor Criteria with at least 1 laboratory abnormality, and exclusion of infectious, malignant, and autoimmune disorders that can mimic iMCD. Characteristic histopathologic features may include a constellation of regressed or hyperplastic germinal centers, follicular dendritic cell prominence, hypervascularization, and polytypic plasmacytosis. Laboratory and clinical Minor Criteria include elevated C-reactive protein or erythrocyte sedimentation rate, anemia, thrombocytopenia or thrombocytosis, hypoalbuminemia, renal dysfunction or proteinuria, polyclonal hypergammaglobulinemia, constitutional symptoms, hepatosplenomegaly, effusions or edema, eruptive cherry hemangiomatosis or violaceous papules, and lymphocytic interstitial pneumonitis. iMCD consensus diagnostic criteria will facilitate consistent diagnosis, appropriate treatment, and collaborative research.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Fajgenbaum DC, Uldrick TS, Bagg A, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood. 2017. PMID: 28087540. doi:10.1182/blood-2016-10-746933

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。